TB-500 Identity Testing: How It Is Confirmed

Short answer

Identity of TB-500 is confirmed by mass spectrometry: the deconvoluted observed mass is compared against the theoretical mass of the claimed sequence, read alongside the RP-HPLC chromatogram. A purity percentage alone cannot confirm identity, because it only states how much of the sample is one substance, never which substance it is.

Key facts

TB-500 is a catalog name with no compendial definition; both full-length thymosin β4 at about 4,963 Da and its 889 Da actin-binding fragment circulate under it.
A purity percentage is an area ratio from a chromatogram and carries no information about which molecule produced the main peak.
Identity rests on an intact-mass measurement, ESI-MS or MALDI-TOF, with the observed mass compared against the theoretical mass of the claimed sequence.
An intact-mass match confirms composition rather than sequence; sequence-level proof takes tandem MS or peptide mapping.
An observed mass 42 Da below theory indicates a chain missing its N-terminal acetyl group, and a +16 Da satellite indicates methionine oxidation.
A certificate that prints the word conforms without an observed mass has asserted identity rather than recorded it.

One name, more than one molecule

TB-500 is a catalog name. No compendial monograph defines it, no pharmacopoeia lists it, and nothing polices what may be sold under it. Most listings describe synthetic thymosin β4, a 43-residue peptide with an acetylated N-terminus and an average mass close to 4,963 Da. Some material in circulation under the same name is a much smaller molecule: the seven-residue actin-binding fragment of that sequence, Ac-LKKTETQ, at roughly 889 Da. Both are real, well-characterized peptides. They are different substances, and the label does not say which one is in the vial.

That makes identity testing more than a formality here. For most single compounds the identity check confirms what everyone already assumed. For TB-500 the name itself is ambiguous, so the identity record is the only place the ambiguity gets resolved. The full-length sequence, at least, is settled ground: the human protein is catalogued in UniProt with its acetylated N-terminus, which is why the theoretical mass a certificate should quote is a fixed number rather than a supplier's opinion.

A laboratory receiving a vial marked TB-500 therefore has one question that comes before any purity discussion. Which molecule is this? The rest of this guide covers how that question gets answered, why the purity figure cannot answer it, and what a certificate has to show before its answer counts as evidence.

Why a purity percentage proves nothing about identity

Purity by reversed-phase HPLC is an area ratio. The sample runs through a column, the eluent is monitored at a wavelength where the peptide bond absorbs, usually 214 to 220 nm, and the main peak's area is divided by the total area of everything that eluted. The number answers one question: of the material that reached this detector, how much was a single substance. It never asks which substance. A cleanly synthesized wrong peptide produces a beautiful purity figure. The 889 Da fragment can run at 99% purity. So can full-length thymosin β4. So can something unrelated to either.

The figure has a second limit that matters for procurement arithmetic. Area percent is not weight percent. Water, residual trifluoroacetate or acetate counterions from synthesis, and inorganic salts neither elute as discrete peaks nor absorb at the detection wavelength, so the purity measurement cannot see them at all. Net peptide content, the fraction of the gross vial weight that is actually peptide, is a separate measurement made by amino acid analysis or nitrogen determination, and on research-market material it commonly sits well below the purity figure.

None of this makes the purity number worthless. It makes it an answer to a narrow question. The ICH specifications guidance for biological products treats identity, purity and content as separate specification classes with separate test procedures, and the separation is the whole point: no one of the three can be inferred from another.

The mass spectrum and what to compare it against

The identity evidence that carries weight on a peptide certificate is an intact-mass measurement. In electrospray ionization (ESI-MS) the peptide picks up several protons and appears as a family of charge states; software deconvolutes the family into a single neutral mass. MALDI-TOF yields a predominantly singly charged ion and reads more directly. Either instrument ends at the same deliverable, an observed mass, which is then set against the theoretical mass calculated from the claimed sequence. Agreement within the instrument's stated tolerance is the identity claim.

For material sold as TB-500 the comparison is unusually decisive, because the candidate molecules sit far apart.

Masses an identity spectrum for material sold as TB-500 can show
Species	What it is	Approximate average mass
Full-length thymosin β4	43 residues, N-terminus acetylated	≈ 4,963 Da
Des-acetyl chain	Same sequence, acetyl group absent	≈ 4,921 Da, 42 Da below the parent
Actin-binding fragment Ac-LKKTETQ	Residues 17–23 of the parent sequence	≈ 889 Da
Oxidized satellite	Methionine sulfoxide at position 6	Parent mass + 16 Da

The 42 Da acetyl difference is a fair illustration of the method's resolution. A routinely calibrated instrument distinguishes 4,921 from 4,963 without difficulty, so a synthesis that skipped the N-terminal acetylation is visible in the very first measurement. Satellite peaks carry information too. A peak 16 Da above the parent is oxidation, and thymosin β4 has exactly one methionine, at position 6, to oxidize. A certificate spectrum with a prominent +16 satellite is telling you something about the lot's handling history, the same chemistry the storage and stability guide walks through for another compound.

What a mass match does not prove

An observed mass that lands on theory confirms that the molecule's composition is consistent with the claimed sequence. It does not read the sequence. Leucine and isoleucine weigh exactly the same. Lysine and glutamine differ by 0.04 Da, which an average-mass measurement of a 5 kDa peptide will not resolve. Two peptides built from the same residues in a different order have identical mass and identical formula. Intact mass narrows the field; it cannot close it.

Sequence-level confirmation takes fragmentation. Tandem MS breaks the intact ion and reads the ladder of fragment masses against the expected backbone. Peptide mapping digests the chain enzymatically and identifies the pieces by LC-MS. Routine supplier certificates rarely go that far, and for a catalog compound they usually do not need to, because chromatography supplies an orthogonal check at much lower cost. Retention time on a reversed-phase column, compared against a qualified reference standard and ideally confirmed by co-injection, is weak evidence on its own; plenty of peptides co-elute. Stacked on a mass match it becomes meaningful, since a wrong molecule now has to reproduce two independent physical properties at once.

That convergence is the actual logic of an identity file. No single measurement is proof. The right mass and the right retention behavior, recorded on the same lot, are jointly hard to satisfy with the wrong substance, and that difficulty is what the certificate is selling.

Reading the certificate

An identity section worth the paper states the technique by name, ESI-MS or MALDI-TOF, and then shows two numbers: the theoretical mass of the claimed sequence and the observed mass for this lot, together, on the same basis. The word conforms standing alone is a claim, not a record; a certificate that asserts identity without printing the observed value has asked to be taken on faith. The chromatogram carrying the purity figure should show its conditions, the detection wavelength, the retention time and the main-peak percentage. And the lot number on the certificate should match the lot number on the vial, because an unlotted document proves nothing about the material in hand.

Specific mismatches to look for with this compound. A listing that describes the 43-residue peptide over a certificate whose observed mass reads near 889 Da is a substitution, whatever the label says. An observed mass 42 Da under theory is the des-acetyl chain. A certificate quoting purity alone, with no identity block at all, has skipped the question this article is about. Certificate artwork that repeats pixel-for-pixel across lots is a template, wherever its numbers came from.

The TB-500 product record carries lot documentation in this format, and the quality standard sets out what every certificate on the catalog is required to show. Verification on arrival, at minimum a check that lot numbers agree and that the observed mass is consistent with the molecule the listing describes, costs minutes and settles the identity question while there is still time to act on the answer.

Regulatory position

TB-500 appears in no approved medicine in the United States and has no USP monograph. The figures in this article come from the primary sequence record and from general mass-spectrometry practice rather than from any compendial standard for the compound itself, and they should be read that way. Thymosin β4 and its derivatives, with TB-500 named as an example, appear on the World Anti-Doping Agency's Prohibited List, a fact about sport governance worth knowing when reading the compound's public footprint. Material sold under the name is a research chemical, supplied for laboratory characterization work of exactly the kind described above. Status verified 25 August 2026.

FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.

Common questions

Is TB-500 the same thing as thymosin beta-4?

Usually that is what the name intends: a synthetic copy of the 43-residue, N-terminally acetylated thymosin β4 sequence. The name has no compendial definition, though, and material corresponding to the short actin-binding fragment of that sequence also circulates under it. The observed mass on the certificate settles the question for a given lot: near 4,963 Da for the full-length chain, near 889 Da for the fragment.

Why isn't a 99% purity figure enough to prove identity?

Because purity is an area ratio from a chromatogram. It states how much of what eluted was a single substance and says nothing about which substance that was. A cleanly made wrong peptide scores just as well as the right one. Identity requires a separate measurement, an observed intact mass compared against the theoretical mass of the claimed sequence, which is why certificates quoting purity alone have not addressed identity at all.

What observed mass should a TB-500 certificate show?

For the full-length acetylated 43-residue chain, an average mass close to 4,963 Da, within the instrument's stated tolerance. A value about 42 Da lower points to a chain missing its N-terminal acetyl group, and a value near 889 Da is the seven-residue actin-binding fragment rather than the full-length peptide. The certificate should print the theoretical figure beside the observed one, so the comparison sits on the page rather than in the reader's head.

Is MALDI-TOF or ESI-MS better for peptide identity?

Both are routine and either is acceptable on a certificate. ESI produces a family of multiply charged ions that software deconvolutes into a neutral mass; MALDI-TOF gives a predominantly singly charged ion read more directly. The choice of ionization matters less than the record: the technique named, the observed mass printed beside its theoretical counterpart, and the measurement tied to the lot number on the vial.

Does a receiving laboratory need to repeat the identity test?

It depends on what the material feeds. Where results will be published or decisions hang on them, an in-house intact-mass check or a co-injection against a reference standard is cheap insurance and standard incoming practice. At minimum, verify that the certificate's lot number matches the vial and that its observed mass is consistent with the molecule the listing describes. A mismatch found at receiving costs an email; one found after the work costs the work.

Sources

UniProt record for human thymosin β4. Establishes the 43-residue sequence and the N-terminal acetylation from which the theoretical mass on a certificate is calculated.
ICH Q6B, specifications guidance for biotechnological and biological products. Establishes identity, purity and content as separate specification classes answered by separate test procedures.
USP general chapter on mass spectrometry. Compendial description of ESI and MALDI measurement and calibration practice underlying intact-mass identity evidence.
World Anti-Doping Agency Prohibited List. Names thymosin β4 and its derivatives, with TB-500 given as an example, among substances prohibited in sport.

TB-500 Identity Testing: How a Laboratory Confirms It